CGTLive®’s Weekly Rewind – October 31, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Quarter Century Update: Where are the Biggest Bottlenecks Today?

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the major friction points in cell and gene therapy development and uptake.

2. M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists

The associate professor of dermatology at Stanford University discussed practical considerations for the introduction of gene therapies in dermatology.

3. Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE

The patient showed grade 4 liver transaminases and increased total bilirubin and was hospitalized.

4. Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis

The chief medical and development officer of Kyverna Therapeutics went over new data the company presented at AANEM’s 2025 meeting.

5. Quarter Century Update: What Does the Field Need Most Right Now?

Phippard shared her thoughts with Brentjens about the importance of big wins for cell and gene therapy research.